New pill aims to slash dangerous lung attacks in bronchiectasis patients
NCT ID NCT07577804
First seen May 14, 2026 · Last updated May 24, 2026 · Updated 2 times
Summary
This study tests a once-daily tablet called CHF10196 (Florensocatib) to see if it can reduce the number of lung flare-ups (exacerbations) in people with bronchiectasis, a chronic lung disease. About 1808 participants aged 12 to 85 will be randomly assigned to receive either the drug or a placebo for up to 78 weeks, followed by an open-label phase where everyone gets the drug. The goal is to improve lung function and quality of life while monitoring safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIECTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.